European Regulators Establish Pediatric Study Plan for Itepekimab

The European Medicines Agency (EMA) has adopted a Paediatric Investigation Plan for the drug itepekimab. These plans are regulatory requirements designed to ensure that sufficient data is collected to support the safe and effective use of medicines in children. This step is crucial for the potential future authorization of the drug for pediatric patients.